The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH. 23
What this version reported
A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.↗↗
- Altimmune, Inc.↗
Trial records: NCT05989711
Reader guide in this version
Key takeaway
Pemvidutide, also known as ALT-801, is an experimental peptide from Altimmune that activates the receptors for two hormones, glucagon and GLP-1.1,2 It is not FDA-approved. A Phase 3 trial in the liver disease MASH was recruiting in August 2026, and none of the sources reviewed here reports an approval in any country.3 In IMPACT, a randomized Phase 2 trial of 212 people with MASH and liver fibrosis, pemvidutide met its goal for resolving MASH at 24 weeks but did not meet its goal for improving fibrosis.2
At a glance
- What it is
- An investigational glucagon and GLP-1 receptor agonist from Altimmune, also known as ALT-801.1,2
- FDA status
- Not FDA-approved. Altimmune has registered a Phase 3 trial in MASH on ClinicalTrials.gov.3
- Human evidence
- One 24-week randomized, double-blind, placebo-controlled Phase 2 trial in 212 people with MASH, with mixed results. Other trials are registered.2,3
- Evidence strength
- Smaller controlled human trials
What is pemvidutide?
Pemvidutide is an experimental peptide being developed by Altimmune, which ClinicalTrials.gov lists as the sponsor of the IMPACT trial. It is also known by its development code, ALT-801.1
The published IMPACT report describes it as a glucagon and GLP-1 receptor agonist studied in metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease with inflammation.2
How is pemvidutide thought to work?
Pemvidutide is designed to activate the receptors for glucagon and GLP-1, two hormones involved in metabolism, appetite and liver fat.2
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2
What do human studies show?
In IMPACT, 212 people with biopsy-confirmed MASH and moderate to advanced liver fibrosis were randomized to pemvidutide or placebo. At 24 weeks, the trial met its goal of MASH resolution without worsening fibrosis.2
It did not meet its second goal, improvement in fibrosis without worsening MASH. Adverse events were reported in 78% and 81% of the pemvidutide groups and 67% of the placebo group.2
A 24-week biopsy result does not show whether people have fewer liver complications over time.2
What the evidence base contains
- Controlled human trial IMPACT (NCT05989711): a randomized, double-blind, placebo-controlled Phase 2 trial in 212 people with biopsy-confirmed MASH and stage F2 or F3 fibrosis, with two liver-biopsy goals at 24 weeks.2
- Registered trial without results A Phase 3 trial in MASH (NCT07795164) listed as recruiting in its August 31, 2026 registry record.3
- Registered trial without results A Phase 2 trial in alcohol use disorder (NCT06987513), listed as completed in its July 31, 2026 record, and a Phase 2 trial in alcohol-associated liver disease (NCT07009860), listed as recruiting.4,5
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is pemvidutide FDA-approved?
No. Pemvidutide remains in clinical trials. None of the sources reviewed here reports an approval of pemvidutide in any country.2,3
As of its August 31, 2026 registry record, a Phase 3 trial of pemvidutide in MASH was listed as recruiting on ClinicalTrials.gov.3
Pemvidutide has also been studied in alcohol use disorder, in a Phase 2 trial listed as completed on July 31, 2026, and is being studied in alcohol-associated liver disease.4,5
Timeline
- 24-week results of the IMPACT Phase 2 trial are published in The Lancet.2
- ClinicalTrials.gov updates the IMPACT record, listing the trial as completed.1
- ClinicalTrials.gov lists a Phase 2 trial in alcohol use disorder as completed.4
- The retained ClinicalTrials.gov record of a Phase 3 trial in MASH lists it as recruiting.3
What is still unknown?
Whether pemvidutide improves liver fibrosis, which IMPACT did not show at 24 weeks.2
What the Phase 3 trial and the alcohol-related trials found or will find: their results are not part of the sources cited here.3,4,5
Sources for this version
- 1IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (2025) · PMID 41237796 ↗
The Lancet · Official source · Source checked November 14, 2026
- 3ClinicalTrials.gov record NCT07795164 · retained source version 2026-08-31:445923515599b1c75e5a12a2ec64209d4453be7d93d0614bca15d8035020d448 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 4ClinicalTrials.gov record NCT06987513 · retained source version 2026-07-31:1e0339600b69d593251060e3e950a1115e96aaa4c5a8b3ff662651ac4049cd93 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 5ClinicalTrials.gov record NCT07009860 · retained source version 2026-03-20:c02a1977625c558c78b022bf4ffb2fb17b8f36e6d148e6e732dd570f2188541e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026